SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Geron Corp.
GERN 3.365-0.1%10:15 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Casaubon4/22/2012 1:15:04 PM
1 Recommendation   of 3549
 
DePinho and Sahin recently published on the adaptive mechanisms provoked by anti-telomerase therapy:

Cell, 2012, v.148, p.651

If anyone is interested in discussing the ramifications to GERN, I would be interested in participating in that conversation. Topics of interest would include how the FDA would respond to the potential for driving a resistance mechanism, given the potential for a sustained positive response in a subset of patients. Also, of interest would be potential oxidative defense drugs, which could be utilized in combination with anti-telomerase therapy, to potentially increase the efficacy of GRN163L.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext